checkAd

HMNC Brain Health embarks on next phase of growth with new leadership team

Nachrichtenquelle: EQS Group AG
22.04.2021, 10:30  |  424   |   |   


DGAP-Media / 22.04.2021 / 10:30

HMNC Brain Health embarks on next phase of growth with new leadership team
  • Benedikt von Braunmühl named new CEO
  • Dr. Hans Eriksson appointed Chief Clinical Development Officer
  • Dr. Franz Humer strengthens Board of Directors as Chairman
  • Founder Prof. Dr. Dr. Dr. h.c. mult. Florian Holsboer to lead Scientific Advisory Board
Munich, April 22, 2021. HMNC Brain Health, a biotech company focused on the development of innovative and personalized treatments for depression and other neuropsychiatric disorders, enters a new phase of growth with a new leadership team. Benedikt von Braunmühl, formerly COO, Diagnostic Services of Medicover, will take over as Chief Executive Officer with effect of May 1, 2021. He will succeed the company founder Prof. Florian Holsboer who already stepped up to the Board of Directors and now also took over the lead of the Scientific Board. Dr. Hans Eriksson, most recently Chief Medical Officer at COMPASS Pathways, further strengthens the Executive Board as Chief Clinical Development Officer.
Dr. Franz Humer, longstanding CEO and Chairman of Roche was appointed Chairman of the Board of Directors. In addition, Adalbert Freiherr von Uckermann, Managing Director of the Jahr Group, joined the Board of Directors as a member. Together with Prof. Holsboer and his co-founder, the entrepreneur Carsten Maschmeyer, the Board of Directors is now composed of four top-class executives.
"Our projects are in a promising state of development and now is the right time to entrust the further steps towards market maturity to a new team that is ideally equipped for this task", said Prof. Holsboer. "Our new Chairman of the Board of Directors, Dr. Franz Humer, brings in decades of experience in the pharmaceutical and diagnostics industry as well as plenty of ideas and a unique network to build further partnerships for growth. As Head of the Scientific Board I remain committed to contribute my expertise with the final goal of making it a reality that patients with mental health conditions like depression can be treated with the right medication", Prof. Holsboer added.
Seite 1 von 4




0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

HMNC Brain Health embarks on next phase of growth with new leadership team DGAP-Media / 22.04.2021 / 10:30 HMNC Brain Health embarks on next phase of growth with new leadership team Benedikt von Braunmühl named new CEO Dr. Hans Eriksson appointed Chief Clinical Development Officer Dr. Franz Humer strengthens Board of …

Nachrichten des Autors

Titel
Titel
Titel
Titel